Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti ☰
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Olanzapina

Zyprexa, Zypadhera e altri

Bibliografia - Quali fonti bibliografiche per Olanzapina?

  1. Aigner M. et al., World J. Biol. Psychiatry, 2011, 12 (6), 400.

  2. Jimenez X., American Accademy of Pain Medicine Annual Meeting, 2016, 18-21 February, Palm Springs, California Abstract 202 http://www.painmed.org/2016posters/abstract-202/ (accesso Maggio 2016)

  3. Arora M., Praharal S.K., Eur. Psychiatry, 2006, 21 (5), 345.2006

  4. Atasoy N. et al., Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31 (6), 1255.

  5. Bachmann S. et al., Br. J. Psychiatry, 1998, 173 (4), 352.

  6. Balestrieri M. et al., Eur. Eat Disord. Rev., 2013, 21 (5), 361.

  7. Beasley C.M. Jr. et al., Neuropsychopharmacology, 1996, 14 (2), 111.

  8. Bodén R. et al., Arch. Gen. Psychiatry, 2012, 69 (7), 715.

  9. Bogunovic O., Viswanathan R., Psychosomatics, 2000, 41 (3), 277.

  10. Brewerton T.D., Curr. Psychiatry Rep., 2012, 14 (4), 398.

  11. Brown C.S. et al., Ann. Pharmacother., 1999, 33 (2), 210.

  12. Brunner E. et al., BMC Pharmacol. Toxicol., 2013, 1, 14.

  13. Bymaster F.P. et al., Neuropsychopharmacology, 1996, 14 (2), 87.

  14. Callaghan J.T. et al., Clin. Pharmacokinet., 1999, 37 (3), 177.

  15. Carillo J.A. et al., Eur. J. Clin. Pharmacol., 2004, 60 (4), 295.

  16. Chew M.L. et al., J. Am. Geriatr. Soc., 2008, 56 (7), 1333.

  17. Ciszowski K. et al., Przegf. Lek., 2011, 68 (8), 426.

  18. Citrome L.L., Jaffe A.B., Ann. Pharmacother., 2003, 37 (12), 1849.

  19. Citrome L. et al., J. Clin. Psychopharmacol., 2009, 29 (3), 278.

  20. Correl C., Manu P. et al., JAMA, 2009, 302, 1765.

  21. Crawford A.M. et al., Schizophr. Res., 1997, 26 (1), 41.

  22. Drug and Therapeutics Bulletin, 2005, vol 43, n 5 maggio, ed. italiana.

  23. Duggal M.K. et al., Am. J. Geriatr. Pharmachoter., 2005, 3 (1), 21.

  24. FDA, Food and Drug Administration, Postmarket Drug Safety Information for Patients and Providers, 2005, 4 novembre disponibile online http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm

  25. FDA, Food and Drug Administration, Label Information for Zyprexa, 2013 disponibile on line http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory

  26. FDA, Food and Drug Administration, Label Information for Symbyax, 2013a disponibile on line http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo

  27. Flanagan R.J., Dunk L., Hum. Psychopharmacol., 2008, 23 Suppl. 1, 27.

  28. Fraguas D. et al., Eur. Neuropsychopharmacol., 2011, 21 (8), 621.

  29. Friedman J.H., J. Pharm. Pract., 2011, 24 (6), 534.

  30. Gardiner S.J. et al., Am. J. Psychiatry, 2003, 160 (8), 1428.

  31. Gilad O. et al., Breastfeed Med., 2011, 6 (2), 55.

  32. Gill S.S. et al., Ann. Intern. Med., 2007, 146 (11), 775.

  33. Gonzalez-Pinto A. et al., J. Affect. Disord., 2011, 131 (1-3), 320.

  34. Gossen D. et al., AAPS PharmSci., 2002, 4 (2), E11.

  35. Grover S. et al., Prim. Care Companion. CNS Disord., 2012, 14 (6), PCC 12I01367.

  36. Grothe D.R. et al., J. Clin. Psychopharmacol., 2000, 20 (2), 220.

  37. Hermann N., Lanctot K.L., CNS Drugs, 2005, 19 (2), 91.

  38. Hiemke C. et al., J. Clin. Psychopharmacol., 2002, 22 (5), 502.

  39. Hori T. et al., Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30 (4), 758.

  40. Informazione sui Farmaci, 2004, anno XXVIII, n 1.

  41. Jones P.B. et al., Arch. Gen. Psychiatry, 2006, 63 (10), 1079.

  42. Joo S.W et al., Clin. Psychopharmacol. Neurosci., 2022, 20 (4), 675.

  43. Kales H.C. et al., Am. J. Psychiatry, 2012, 169 (1), 71.

  44. Kane J.M. et al., Am. J. Psychiatry, 2010, 167 (2), 181.

  45. Khaldi S. et al., Encephale, 2008, 34 (6), 618.

  46. Kemp D.E. et al., J. Clin. Psychiatry, 2011, 72 (9), 1236.

  47. Kishi T. et al., J. Clin. Psychiatry, 2012, 73 (6), e757.

  48. Kuehn B.M. et al., JAMA, 2010, 303 (16), 1582.

  49. Lancet, 1997, 349, 1264.

  50. Lauriello J. et al., J. Clin. Psychiatry, 2008, 69 (5), 790.

  51. Leucht S. et al., Lancet, 2009, 373 (9657), 31.

  52. Leucht S. et al., Lancet, 2013, 382 (9896), 951.

  53. Lieberman J.A. et al., NEJM, 2005, 353 (12), 1209.

  54. Lindenmayer J.P., Neuropsychiatr. Dis. Treat., 2010, 6, 261.

  55. Lobo E.D. et al., Paediatr. Drugs, 2010, 12 (3), 201.

  56. Lucas R.A. et al., Eur. J. Clin. Pharmacol., 1998, 54 (8), 639.

  57. Macias W.L. et al., Pharmacotheapy, 1998, 18 (6), 1237.

  58. Marder S.R. et al., J. Clin. Psychiatry, 2010, 71 (4), 433.

  59. Marras C. et al., Am. J. Geriatr. Pharmacother., 2012, 10 (6), 381.

  60. Maurier F et al., Eur. J. Clin. Pharmacol., 2010, 66 (5), 531.

  61. McCormack P.L., CNS Drugs, 2010, 24 (5), 443.

  62. McDonagh M. et al., Drug Class Reviews, luglio 2010, Oregon Health & Science University.

  63. McDonnell D.P. et al., BMC Psychiatry, 2010, 10, 45.

  64. Mehta A., Sanitato J., Psychiatry (Edgmont), 2005, 2 (9), 18.

  65. Moteshafi H. et al., Drug Saf., 2012, 35 (10), 879.

  66. National Institute for Health and Clinical Excellence - NICE, Schizophrenia, 2010 disponibile online www.nice.org.uk/nicemedia/pdf/cg82fullguideline.pdf

  67. Newport D.J. et al., Am. J. Psychiatry, 2007, 164 (8), 1214.

  68. Ondo W.G. et al., Mov. Disord., 2002, 17 (5), 1031.

  69. Onofrj M., Thomas A., Eur. Neurol., 2001, 45 (1), 56.

  70. Pae C.U. et al., Int. Clin. Psychopharmacol., 2005, 20 (3), 173.0000

  71. Papaioannides D. et al., Int. J. Low Extrem. Wounds., 2006, 5 (2), 116.

  72. Patra B.N. et al., Indian J. Pharmacol., 2013, 45 (1), 98.

  73. Peterson A.B. et al., Clin. Toxicol. (Phila), 2013, Dec. 9.

  74. Pottegard A. et al., Br. J. Clin. Pharmacol., 2018, 84 (9), 2152.

  75. Rai S. et al., Indian J. Pharmacol., 2004, 36 (3), 186.

  76. Rendell J.M. et al., Cochrane Database Syst. Rev., 2003, (3), CD004040.

  77. Ribeyron S. et al., Rev. Med. Intern., 2009, 30 (6), 477.

  78. Rowe M. et al., Ther. Adv. Psycopharmacol., 2012, 2 (6), 265.

  79. Sathirakul K. et al., Br. J. Clin. Pharmacol., 2003, 56 (2), 184.

  80. Seppi K et al., Mov. Disord., 2011, 26 Suppl. 3, S42.

  81. Shulman M. et al., Minerva Med., 2013, 104 (2), 175.

  82. Silva M.T. et al., J. Affect. Disord., 2013, 146 (3), 310.

  83. Sistema nazionale per le linee guida SNLG, Gli interventi precoci nella schizofrenia, 2009 disponibile on line http://www.snlg-iss.it/lgn_schizofrenia.

  84. Stip E. et al., Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31 (1), 297.

  85. Suzuki Y. et al., Hum. Psychopharmacol., 2011, 26 (6), 440.

  86. Suzuki Y. et al., Hum. Psychopharmacol., 2013, 28 (3), 215.

  87. Taipale H. et al., Lancet Psychiatry, 2021, 8 (10), 883.

  88. Tohen M. et al., Arch. Gen. Psychiatry, 2003, 60 (11), 1079.

  89. UKTIS, UK Teratology Information Service, Use of olanzapine in pregnacy, 2010, novembre, disponibile on line http://www.uktis.org/Search/search.php?FormsButton1.x=0&FormsButton1.y=0&zoom_query=olanzapine

  90. Waage C. et al., JOP, 2004, 5 (5), 388.

  91. Woerner M.G. et al., Neuropsychopharmacology, 2011, 36 (8), 1738 disponible on line http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138649/

  92. Zahodne L.B., Fernandez H.H., Drugs Aging, 2008, 25 (8), 665.